{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:43Z","timestamp":1790707243073,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). Unlike lenalidomide, the role of bortezomib in consolidation and maintenance therapy for MM is less clear. We performed a meta-analysis to evaluate the impact of bortezomib-based consolidation and maintenance therapy on survival outcomes and adverse events. PubMed, Web of Science, Embase databases, and major conference proceedings were searched for randomized controlled trials (RCTs) of bortezomib-based regimens as consolidation or maintenance therapy for MM. Ten RCTs enrolling 3147 patients were included in the meta-analysis. Bortezomib-based regimens were compared with regimens without bortezomib or observation. The meta-analysis suggested that bortezomib-based maintenance therapy improved progression-free survival (PFS; hazard ratio [HR]\u2009=\u20090.72, 95% CI 0.55\u20130.95,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02) and overall survival (OS; HR\u2009=\u20090.71, 95% CI 0.58\u20130.87,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001). Bortezomib-based consolidation therapy improved PFS (HR\u2009=\u20090.77, 95% CI 0.68\u20130.88,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) but not OS (HR\u2009=\u20090.98, 95% CI 0.78\u20131.24,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.87). Bortezomib-based consolidation\/maintenance therapy led to a trend toward increased risk of grade\u2009\u2265\u20093 neurologic symptoms, gastrointestinal symptoms, and fatigue. More research is warranted to further assess the role of bortezomib-based consolidation and maintenance therapy for multiple myeloma.\n                  <\/jats:p>","DOI":"10.1038\/s41408-020-0298-1","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T09:12:25Z","timestamp":1583485945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-9255","authenticated-orcid":false,"given":"Shijia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"298_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian, D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin. Oncol. 43, 676\u2013681 (2016).","journal-title":"Semin. Oncol."},{"key":"298_CR2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"298_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.89","volume":"6","author":"B Lipe","year":"2016","unstructured":"Lipe, B., Vukas, R. & Mikhael, J. The role of maintenance therapy in multiple myeloma. Blood Cancer J. 6, e485 (2016).","journal-title":"Blood Cancer J."},{"key":"298_CR4","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770\u20131781 (2012).","journal-title":"N. Engl. J. Med."},{"key":"298_CR5","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"298_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/107327480301000502","volume":"10","author":"PG Richardson","year":"2003","unstructured":"Richardson, P. G., Hideshima, T. & Anderson, K. C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 10, 361\u2013369 (2003).","journal-title":"Cancer Control."},{"key":"298_CR7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906\u2013917 (2008).","journal-title":"N. Engl. J. Med."},{"key":"298_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie, B. G. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"298_CR9","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, Bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"key":"298_CR10","unstructured":"Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART). https:\/\/www.msmart.org\/mm-treatment-guidelines. Accessed 31 Dec 2018."},{"key":"298_CR11","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 339, b2535 (2009).","journal-title":"BMJ."},{"key":"298_CR12","doi-asserted-by":"crossref","unstructured":"Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R. Introduction to Meta\u2010Analysis (Wiley, 2009).","DOI":"10.1002\/9780470743386"},{"key":"298_CR13","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst. 22, 719\u2013748 (1959).","journal-title":"J. Natl Cancer Inst."},{"key":"298_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177\u2013188 (1986).","journal-title":"Control Clin. Trials"},{"key":"298_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"key":"298_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 50, 1088\u20131101 (1994).","journal-title":"Biometrics."},{"key":"298_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.55","volume":"6","author":"SJ Jacobus","year":"2016","unstructured":"Jacobus, S. J. et al. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J. 6, e448 (2016).","journal-title":"Blood Cancer J."},{"key":"298_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"M-V Mateos","year":"2010","unstructured":"Mateos, M.-V. et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11, 934\u2013941 (2010).","journal-title":"Lancet Oncol."},{"key":"298_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer, E. A. et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J. Clin. Oncol. 37, 589\u2013597 (2019).","journal-title":"J. Clin. Oncol."},{"key":"298_CR20","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1080\/10428194.2019.1579322","volume":"60","author":"N Horvath","year":"2019","unstructured":"Horvath, N. et al. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leuk. Lymphoma 60, 2122\u20132133 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"298_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/leu.2017.83","volume":"31","author":"H Einsele","year":"2017","unstructured":"Einsele, H. et al. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Leukemia 31, 1463\u20131466 (2017).","journal-title":"Leukemia"},{"key":"298_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.14637","volume":"178","author":"O Sezer","year":"2017","unstructured":"Sezer, O. et al. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br. J. Haematol. 178, 61\u201371 (2017).","journal-title":"Br. J. Haematol."},{"key":"298_CR23","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/leu.2017.35","volume":"31","author":"L Rosinol","year":"2017","unstructured":"Rosinol, L. et al. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial. Leukemia. 31, 1922\u20131927 (2017).","journal-title":"Leukemia."},{"key":"298_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J. Clin. Oncol. 32, 634\u2013640 (2014).","journal-title":"J. Clin. Oncol."},{"key":"298_CR25","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","volume":"121","author":"UH Mellqvist","year":"2013","unstructured":"Mellqvist, U. H. et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 121, 4647\u20134654 (2013).","journal-title":"Blood."},{"key":"298_CR26","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946\u20132955 (2012).","journal-title":"J. Clin. Oncol."},{"key":"298_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","volume":"120","author":"M Cavo","year":"2012","unstructured":"Cavo, M. et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 120, 9\u201319 (2012).","journal-title":"Blood."},{"key":"298_CR28","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 35, 3279\u20133289 (2017).","journal-title":"J Clin Oncol."},{"key":"298_CR29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo, M. et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 376, 2075\u20132085 (2010).","journal-title":"Lancet."},{"key":"298_CR30","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","volume":"28","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau, H. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630\u20134634 (2010).","journal-title":"J. Clin. Oncol."},{"key":"298_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael, J. R. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88, 360\u2013376 (2013).","journal-title":"Mayo Clin. Proc."},{"key":"298_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.23","volume":"7","author":"S Sengsayadeth","year":"2017","unstructured":"Sengsayadeth, S., Malard, F., Savani, B. N., Garderet, L. & Mohty, M. Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J. 7, e545 (2017).","journal-title":"Blood Cancer J."},{"key":"298_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben, K. et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 119, 940\u2013948 (2012).","journal-title":"Blood."},{"key":"298_CR34","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau, J. L. et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J. Clin. Oncol. 28, 4621\u20134629 (2010).","journal-title":"J. Clin. Oncol."},{"key":"298_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.V122.21.404.404","volume":"122","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld, P. et al. Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: extended follow-up of the HOVON-65\/GMMG-HD4 Trial. Blood. 122, 404\u2013404 (2013).","journal-title":"Blood."},{"key":"298_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt, H. et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia. 32, 383\u2013390 (2018).","journal-title":"Leukemia."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0298-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0298-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0298-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:26:27Z","timestamp":1670232387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0298-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0298-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"2 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Michael Wang made the following disclosures: research grants, consulting\/advisory board, and honoraria\u2014Janssen and Acerta Pharma; research grants and consulting\/advisory board\u2014Pharmacyclics, AstraZeneca, Celgene, Juno Therapeutics, Loxo Oncology, Kite Pharma, and BioInvent; research grants\u2014BeiGene, VelosBio, and Aviara; consulting\/advisory board\u2014Pulse Biosciences and Guidepoint Global; consulting\/advisory board and stock\u2014MoreHealth; honoraria\u2014OMI, Physicians Education Resources, and Oncology News, outside the submitted work. Dr. Veronika Bachanova reported non-financial support from ArticulateScience, grants from Novartis, grants from GT Biopharma, personal fees from Seattle Genetics, Kite Pharma, and Zymogen, outside the submitted work. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"33"}}